Novel Constructs—Half-Life Extensions

A dearth of biologics have been developed and used as therapeutics for numerous disease indications, including IgG monoclonal antibodies, non-IgG recombinant proteins, bi- and multi-specific antibodies, and antibody drug conjugates. A remarkable portion of these biologic constructs exhibits a short plasma half-life that results in a significant reduction in therapeutic efficacy. Frequently, biologic drugs need to be designed to maintain the effective concentration range during the therapeutic window with an extended serum half-life. Provided here is a comprehensive overview of various half-life extension methods involving FcRn engagement, chemical and genetic fusion, post-translational modifications and formulation.